Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IBRXBearishCorporate Developmentsnews

High materiality8/10

ImmunityBio Misses Q1 Earnings, Stock Declines Despite Revenue Growth

May 7, 2026, 2:11 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The earnings miss may lead to reduced investor confidence, reflecting a pattern—missed estimates often cause significant stock declines in biotech.

AI summary

What happened, with direct paths to the underlying reporting

ImmunityBio's first-quarter results suffered a loss of 62 cents, missing analyst expectations, despite sales surging 168% year-over-year to $44.21 million, driven by Anktiva's performance. These mixed results have led to an 11.46% decline in share price, indicating investor uncertainty moving forward.

ImmunityBio reported a Q1 loss of 62 cents, missing expectations.
Sales reached $44.21 million, beating estimates with a 168% increase.
Anktiva drug sales drove product revenue growth significantly.
Stock faces technical challenges despite impressive annual performance.
IBRX is down 11.46% to $7.42 amid these results.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

ImmunityBio Misses Q1 Earnings, Stock Declines Despite Revenue Growth

Emirates approves ANKTIVA, expanding IBRX footprint and potential catalysts

ImmunityBio's ANKTIVA Shows Promising Results, But Shares Decline

ImmunityBio's ANKTIVA Launch in Saudi Arabia Boosts IBRX Stock

ImmunityBio Faces Class Action Over Misleading Drug Claims